Physician profile
Deka A Efobi
NPI 1720059397
$393.85
in general payments reported to CMS, 2019-2025
16 companies · $40.79 in 2025
The $40.79 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.74 · 2020: $49.87 · 2021: $119 · 2022: $62.60 · 2023: $14.52 · 2024: $38.91 · 2025: $40.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $94.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $94.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $62.77 | 2020-2021 | |
| Abbvie INC. | $50.77 | 2021-2024 | |
| Ucb, INC. | $46.13 | 2022 | |
| Amgen INC. | $25.06 | 2021 | |
| Amneal Pharmaceuticals LLC | $23.79 | 2021 | |
| Lilly USA, LLC | $23.19 | 2025 | Kisunla, Amyvid |
| Emd Serono, INC. | $21.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.18 | 2019 | |
| Livanova USA, INC. | $18.51 | 2021 | |
| Genentech USA, INC. | $17.60 | 2025 | Ocrevus Zunovo |
| Janssen Pharmaceuticals, INC | $16.47 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.52 | 2023 | Ultomiris |
| Alfasigma USA, INC. | $13.71 | 2021 | |
| Csl Behring | $13.65 | 2019 | |
| Tempus Ai, INC | $13.59 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $13.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deka Efobi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.